US EditionGilead's CAR-T cell therapy shows promise in deadly brain cancer
- Researchers at Washington University led an international Phase 1/2 trial of WU-CART-007, a new CAR-T cell therapy for aggressive T cell cancers in adolescents and adults.
- The trial enrolled 28 patients whose cancers relapsed after multiple treatments or never responded, reflecting a critical unmet need with less than 7% five-year survival.
- Results showed a 91% overall response rate and 72.7% complete remission, significantly surpassing standard therapy remission rates of 20-40%, with mostly mild or moderate side effects.
- The universal therapy, developed using CRISPR and produced from healthy donors' cells, targets any patient with T cell cancer and may serve as a bridge-to-transplant treatment.
- Researchers emphasize completing larger trials to confirm curative potential, as this immunotherapy could transform treatment for patients with deadly, resistant T cell cancers.
18 Articles
18 Articles
Gilead's CAR-T cell therapy shows promise in deadly brain cancer
A Gilead Sciences-backed therapy made with a patient's own white blood cells shrank tumors in 62% of patients with recurrent glioblastoma, a rare event for a fatal brain cancer with few treatment options, researchers reported on Sunday.
Universal CAR T cell therapy shows promise for aggressive T cell cancers
A new type of immunotherapy that targets aggressive blood cancers shows promising results alongside manageable side effects, according to the results of an international phase 1/2 clinical trial led by researchers at Washington University School of Medicine in St. Louis.
Medical Xpress
Science DailyInnovative immunotherapy shows promise against aggressive T cell cancers
A new type of immunotherapy that targets aggressive blood cancers shows promising results alongside manageable side effects, according to the results of an international Phase I/II clinical trial led by researchers at Washington University School of Medicine in St. Louis.
Scienmag: Latest Science and Health News
BIOENGINEER.ORGDual-Targeted CAR T Cell Therapy Shows Promise in Slowing Aggressive Brain
In a groundbreaking leap forward for brain cancer treatment, researchers from the University of Pennsylvania have unveiled promising results from a novel dual-target CAR T cell therapy aimed at recurrent glioblastoma (GBM), one of the most aggressive and lethal brain tumors known to medicine. This innovative approach employs a personalized immunotherapy strategy that harnesses the patient’s own immune cells, genetically engineered to recognize a…
Universal chimeric antigen receptor T cell therapy — The future of cell therapy: A review providing clinical evidence
Autologous CAR-T therapy has shown promising outcomes in the treatment of tumors, particularly hematological malignancies over the past years. However…
Coverage Details
Bias Distribution
- 60% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
